rs76702162
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM1PM2PM5PP2PP3_StrongPP5
The NM_000138.5(FBN1):c.6448C>T(p.Arg2150Cys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000657 in 152,218 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R2150H) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000138.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
FBN1 | NM_000138.5 | c.6448C>T | p.Arg2150Cys | missense_variant | 53/66 | ENST00000316623.10 | |
FBN1 | NM_001406716.1 | c.6448C>T | p.Arg2150Cys | missense_variant | 52/65 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
FBN1 | ENST00000316623.10 | c.6448C>T | p.Arg2150Cys | missense_variant | 53/66 | 1 | NM_000138.5 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.00000657 AC: 1AN: 152100Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000797 AC: 2AN: 251026Hom.: 0 AF XY: 0.00000737 AC XY: 1AN XY: 135656
GnomAD4 exome Cov.: 30
GnomAD4 genome ? AF: 0.00000657 AC: 1AN: 152218Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74426
ClinVar
Submissions by phenotype
Familial thoracic aortic aneurysm and aortic dissection Pathogenic:1Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Aug 17, 2022 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | May 08, 2023 | The p.R2150C variant (also known as c.6448C>T), located in coding exon 52 of the FBN1 gene in the cb EGF-like #32 domain, results from a C to T substitution at nucleotide position 6448. The arginine at codon 2150 is replaced by cysteine, an amino acid with highly dissimilar properties. The majority of FBN1 mutations identified to date have involved the substitution or generation of cysteine residues within cbEGF domains (Vollbrandt T et al. J Biol Chem. 2004;279(31):32924-32931). This alteration has been observed in individuals with clinical features of Marfan syndrome (Turner CL et al. Am J Med Genet A, 2009 Feb;149A:161-70, Mannucci L et al. Clin Chim Acta, 2020 Feb;501:154-164). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
not provided Pathogenic:1Uncertain:1
Uncertain significance, flagged submission | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 21, 2016 | Variant summary: The FBN1 c.6448C>T (p.Arg2150Cys) causes a missense change involving a conserved nucleotide located in a EGF-like domain, which 4/4 in silico programs (SNPs&GO not captured here due to low reliability index) predict a "damaging" outcome, although these predictions have yet to be functionally assessed. The variant alters an Arginine to Cysteine. Cysteines are vital for proper FBN1 function and alterations, although this variant creates another Cysteine instead of eliminating a Cysteine, it could lead to disruption of disulfide binding, secondary or tertiary structure, or possibly impairing fibrillin interactions. The variant of interest was observed in the large, broad control population, ExAC, with an allele frequency of 2/121088 (1/60544), which does not exceed the estimated maximal expected allele frequency for a pathogenic FBN1 variant of 1/8888. The variant of interest has been reported in one affected individual via a publication that does not fulfill the Ghent criteria. In addition, the variant of interest has been cited by multiple clinical diagnostic laboratories/databases with a classification of "uncertain significance." Therefore, due to the nature of this variant, the variant of interest has been classified as a "Variant of Uncertain Significance - Possibly Pathogenic," until additional information becomes available. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 18, 2023 | Not observed at significant frequency in large population cohorts (gnomAD); Identified independently and in conjunction with additional cardiogenetic variants in individuals referred for TAAD, Marfan syndrome, and related disorders at GeneDx, but segregation data is limited or absent at this time; Introduces a new cysteine residue within a calcium-binding EGF-like domain of the FBN1 gene, which may affect disulfide bonding and is predicted to alter the structure and function of the protein; cysteine substitutions in the calcium-binding EGF-like domains represent the majority of pathogenic missense changes associated with FBN1- related disorders (Collod-Beroud et al., 2003); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 26332594, 19161152, 33059708, 31730815, 12938084) - |
Marfan syndrome;C4707243:Familial thoracic aortic aneurysm and aortic dissection Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jan 13, 2024 | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 2150 of the FBN1 protein (p.Arg2150Cys). This variant is present in population databases (rs76702162, gnomAD 0.004%). This missense change has been observed in individual(s) with clinical features of Marfan syndrome (PMID: 19161152, 31730815; Invitae). ClinVar contains an entry for this variant (Variation ID: 200084). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FBN1 protein function with a positive predictive value of 95%. This variant disrupts the p.Arg2150 amino acid residue in FBN1. Other variant(s) that disrupt this residue have been observed in individuals with FBN1-related conditions (PMID: 28973303, 31098894; Invitae), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at